Repligen | RGEN - Operating Profit


Repligen reported $24.31M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Agilent USD 444M 45M Jun/2026
Align Technology USD 193.04M 1.72M Sep/2026
Bio Techne USD 55.82M 39.18M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Bruker USD 83.5M 13.9M Sep/2026
Charles River Laboratories USD 202.64M 82.75M Sep/2026
Danaher USD 1.25B 118M Sep/2026
Dentsply International USD 38M 46M Sep/2026
General Electric Aerospace USD 2.22B 338M Sep/2026
Henry Schein USD 193M 7M Sep/2026
Illumina USD 305M 45M Sep/2026
IQVIA Holdings USD 608M 1.99B Sep/2026
Mettler Toledo International USD 287.55M 53.61M Jun/2026
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Pfizer USD 662M 5M Sep/2026
Repligen USD 24.31M 3.18M Sep/2026
Revvity USD 124.63M 1.51M Sep/2026
Standard Biotools USD -7.83M 1.59M Jun/2026
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
Waters USD -86M 234M Jun/2026
West Pharmaceutical Services USD -199.7M 378.8M Sep/2026